CEO — Clinical-Stage Biotech

JOlivier & Partners has been retained by the board of an Oxford-based clinical-stage biotech to identify a new CEO to lead through Phase 3 trials and potential NASDAQ IPO or pharma partnership.

The Organisation & Context

Our client is an Oxford University spin-out developing a first-in-class oncology therapeutic with a Phase 3 trial reading out in 18 months, $120m in funding and a strong IP estate.

Key Responsibilities

• Lead the executive team through Phase 3 completion and regulatory submissions
• Define the business development strategy — partnership vs IPO
• Manage investor relationships and lead the next financing round ($150-200m)
• Build commercial infrastructure for potential product launch
• Represent the company at scientific and regulatory forums

Candidate Profile

• CEO or COO at a clinical-stage biotech or specialty pharma
• Track record of Phase 3 leadership and regulatory approval or major partnership
• Experience with NASDAQ IPO preparation or major pharma licensing
• Deep credibility with scientific leadership and institutional investors